🔗 Share this article

This year's prestigious award in medical science was granted for transformative findings that illuminate how the body's defense network targets dangerous infections while sparing the healthy tissues.

A trio of esteemed researchers—Japan's Prof. Sakaguchi and American scientists Mary Brunkow and Fred Ramsdell—share this accolade.

Their work uncovered unique "sentinels" within the immune system that remove rogue defense cells capable of attacking the organism.

The discoveries are now enabling innovative therapies for autoimmune diseases and malignancies.

These winners will divide a monetary award valued at 11m SEK.

Crucial Discoveries

"The work has been essential for understanding how the body's defenses functions and the reason we don't all develop serious autoimmune diseases," commented the chair of the Nobel Committee.

The trio's studies address a core question: How does the immune system protect us from countless invaders while keeping our own tissues unharmed?

The body's protection system employs white blood cells that scan for indicators of disease, even viruses and germs it has never encountered.

These defenders utilize detectors—called receptors—that are generated by chance in countless variations.

That gives the immune system the capacity to combat a wide array of invaders, but the randomness of the process inevitably produces immune cells that can target the body.

Protectors of the Body

Scientists earlier knew that a portion of these problematic defense cells were destroyed in the thymus—where white blood cells develop.

The latest Nobel Prize honors the discovery of regulatory T-cells—described as the body's "security guards"—which travel through the body to neutralize any immune cells that assault the healthy cells.

It is known that this process fails in self-attack conditions such as type-1 diabetes, multiple sclerosis, and rheumatoid arthritis.

The Nobel panel added, "The findings have laid the foundation for a new field of investigation and spurred the development of innovative therapies, for example for tumors and autoimmune diseases."

Regarding cancer, regulatory T-cells block the system from attacking the tumor, so studies are focused on lowering their quantity.

In self-attack disorders, trials are exploring increasing regulatory T-cells so the body is not under attack. A comparable method could also be useful in reducing the risks of organ transplant failure.

Innovative Experiments

Professor Sakaguchi, of a Japanese institution, conducted tests on mice that had their immune gland removed, leading to self-attack conditions.

He demonstrated that injecting immune cells from healthy mice could stop the disease—suggesting there was a mechanism for preventing immune cells from harming the host.

Mary Brunkow, from the a research center in a US city, and Fred Ramsdell, now at a biotech firm in San Francisco, were studying an genetic autoimmune disease in rodents and humans that resulted in the discovery of a genetic factor vital for the way T-regs function.

"The groundbreaking work has uncovered how the immune system is kept in check by regulatory T cells, stopping it from mistakenly targeting the body's own tissues," commented a leading physiology specialist.

"This research is a remarkable illustration of how basic biological research can have broad implications for human health."